Overview

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Janssen Research & Development, LLC
Treatments:
Ustekinumab